A randomized controlled pilot study examining the impact of exercise on sleep quality (SQ) and sleep modulating cytokines among breast and prostate cancer (BC & PC) patients receiving radiation (RTH)

2010 ◽  
Author(s):  
Karen Mustian ◽  
Oxana Palesh ◽  
Lisa Sprod ◽  
Luke Peppone ◽  
Charles Heckler ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Sleep Quality ◽  
Randomized Controlled ◽  
Breast And Prostate Cancer ◽  
The Impact

scholarly journals Exercise, sleep quality, and mediators of sleep in breast and prostate cancer patients receiving radiation therapy

2010 ◽  
Vol 7 (10) ◽  
pp. 463-471 ◽  
Author(s):  
Lisa K. Sprod ◽  
Oxana G. Palesh ◽  
Michelle C. Janelsins ◽  
Luke J. Peppone ◽  
Charles E. Heckler ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Sleep Quality ◽  
Cancer Patients ◽  
Breast And Prostate Cancer

The impact of the ASCO Choosing Wisely campaign for breast and prostate cancer on physician behavior.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 6592-6592
Author(s):  
Danielle Lee Rodin ◽  
Pragya Kakani ◽  
Meredith Rosenthal ◽  
Anna Sinaiko
Keyword(s):  
Prostate Cancer ◽  
Physician Behavior ◽  
Choosing Wisely ◽  
Breast And Prostate Cancer ◽  
The Impact

Interim analysis of a pilot study: Impact of high-dose, single fraction radiation on immunogenicity of sipuleucel-T in metastatic castration resistant prostate cancer patients.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16538-e16538
Author(s):  
Yuanquan Yang ◽  
Saby George ◽  
Ellis Glenn Levine ◽  
Thomas Schwaab ◽  
Jason Muhitch ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Pilot Study ◽  
Bone Lesion ◽  
Post Treatment ◽  
High Dose ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Incorporation Assay ◽  
The Impact

e16538 Background: Sipuleucel-T is known to have modest anti-tumor activity in pts with metastatic castration resistant prostate cancer (mCRPC). Synergy of radiotherapy and immunotherapy has been reported. We conducted a pilot study to assess the impact of radiation on immunogenicity of Sipuleucel-T. Methods: Pts with minimally symptomatic mCRPC and bone metastases were eligible. Pts received Sipuleucel-T every 2 wks x 3 infusions. 8 Gy RT to 1 bone lesion was given 2 days after the first infusion. Peripheral blood was collected at D0, 7d after each infusion, 3 and 6 m. Primary endpoint is the effect of RT on immunogenicity of Sipuleucel-T. Secondary endpoints were safety, PSA changes and survival. We will evaluate T cell proliferation and cytolytic response at baseline and post-treatment using thymidine incorporation assay, IFN-y ELISPOT and flow cytometry. Results: From 10/2013 to 7/2018, a total of 15 pts were enrolled. Median age was 69 years (59-77). 10 pts (67%) had GS > = 8 disease. 7 pts (47%) failed prior abiraterone or enzalutamide. 13 pts completed treatment per protocol (2 withdrew). During a median follow-up of 48 mos, the 3-year overall survival was 48% (95% CI, 21-71); median survival was 30.7 mos (95% CI, 14.6-NR). No PSA responses were observed. 11 pts had post-treatment imaging (non-mandatory). 10 had PD and 1 had SD. 10 pts (67%) had Grade 1-2 drug-related AEs (most common: dizziness and hematoma 20%). No DLT or grade 3-5 drug-related AEs were observed. Conclusions: Sipuleucel-T plus RT is well tolerated. Median overall survival in this limited subset of pts was encouraging, when compared with historical data (25.8 mos in IMPACT trial). The evaluation of immune response is ongoing. (Funded by DENDREON; ClinicalTrials.gov ID: NCT01833208) Clinical trial information: NCT01833208.

scholarly journals The Impact of a Randomized Controlled Trial of a Lifestyle Intervention on Sleep Among Latina Postpartum Women

2021 ◽  
Author(s):  
Marquis Hawkins ◽  
Bess Marcus ◽  
Penelope Pekow ◽  
Milagros C Rosal ◽  
Katherine L Tucker ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Sleep Quality ◽  
Sleep Duration ◽  
Controlled Trial ◽  
Postpartum Women ◽  
Health And Wellness ◽  
Latina Women ◽  
Onset Latency ◽  
Randomized Controlled ◽  
The Impact

Abstract Background Poor sleep is associated with adverse outcomes among postpartum women. Exercise may improve sleep, but this has not been well examined in the postpartum period. Purpose To examine the impact of a culturally modified, individually tailored lifestyle intervention on sleep outcomes among postpartum Latina women. Methods Estudio PARTO was a randomized controlled trial aimed at reducing Type 2 diabetes among Latina women with abnormal glucose tolerance in pregnancy. Participants were randomized to a lifestyle (i.e., diet and exercise; n = 70) or a health and wellness control intervention (n = 78) in late pregnancy (baseline). The Pittsburgh Sleep Quality Index (PSQI) was used to measure sleep quality (PSQI score), onset latency (minutes per night), duration (hours per night), efficiency (percentage of the time in bed asleep), and daytime dysfunction at baseline, 6 weeks, 6 months, and 12 months postpartum. Results Mean PSQI score (6.56 ± 3.87), sleep duration (6.84 ± 1.75 hr/night), and sleep efficiency (79.70% ± 18.10%) did not differ between the arms at baseline. Mixed-effects models indicated a greater decrease of 1.29 in PSQI score (i.e., improved sleep quality) in the lifestyle versus health and wellness arm (95% confidence interval [CI] = −2.50 to −0.08, p = .04) over follow-up. There was the suggestion of a smaller decrease in sleep duration (mean = 0.48 hr/night, 95% CI = −0.10 to 1.06, p = .10) in the lifestyle versus health and wellness arm. There were no statistically significant differences in other sleep outcomes between arms. Conclusions Findings suggest that lifestyle interventions improve sleep quality but not sleep duration, sleep onset latency, sleep efficiency, or daytime dysfunction in postpartum Latina women and, therefore, may hold promise for improving subsequent mental and physical health in this population. Clinical Trials Registration NCT01679210.

scholarly journals Investigating the impact of open label design on patient‐reported outcome results in prostate cancer randomized controlled trials

2020 ◽  
Vol 9 (20) ◽  
pp. 7363-7374
Author(s):  
Guillaume Mouillet ◽  
Fabio Efficace ◽  
Antoine Thiery‐Vuillemin ◽  
Emilie Charton ◽  
Mieke Van Hemelrijck ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Randomized Controlled Trials ◽  
Patient Reported Outcome ◽  
Controlled Trials ◽  
Open Label ◽  
Randomized Controlled ◽  
Patient Reported ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document